Intra-oral nanoemulsion including monolayer surfactant bound particles for balancing histamine response
AssigneeQuicksilver Scientific, Inc.
InventorsChristopher W. Shade, Steven Tieu
Life of this patent
Estimating the term…
Abstract
An intra-oral, nanoemulsion assists in balancing the histamine response in subjects when orally administered. The intra-oral, nanoemulsion includes at least one monolayer surfactant bound particle and a continuous phase. The monolayer surfactant bound particles are carried by the continuous phase. A method of making and of administering the nanoemulsion to balance the histamine response in subjects also is described. The nanoemulsion is ingestible and edible.
Claims25
An intra-oral nanoemulsion for balancing the histamine response in a subject when intra-orally administered, the nanoemulsion comprising:
- at least one monolayer surfactant bound particle, where
- the at least one monolayer surfactant bound particle comprises at least one amphiphilic fat, a polyethylene glycol surfactant, an associating oil, diindolylmethane, quercetin, and luteolin, where the diindolylmethane, the quercetin, and the luteolin are solubilized in the at least one monolayer surfactant bound particle;
- and
- a continuous phase comprising glycerin, ethanol, and water;
- where
- the at least one monolayer surfactant bound particle has a ratio of the amphiphilic fat to the polyethylene glycol surfactant from 1:1.8 to 1:3 by weight,
- the at least one amphiphilic fat is chosen from phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), ceramide phosphoryl ethanolamine (Cer-PE), ceramide phosphoryl choline (SPH), and combinations thereof,
- the polyethylene glycol surfactant is chosen from TPGS, polysorbate 80, polysorbate 60, and combinations thereof,
- the associating oil is chosen from medium chain triglycerides (MCT), citrus oil, and combinations thereof,
- the nanoemulsion is a stable dispersion that is transparent, and
- the at least one monolayer surfactant bound particle has an average particle diameter from 10 to 100 nanometers as carried by the continuous phase.
A method of balancing histamine response in a subject, the method comprising:
- holding from 4 to 6 milliliters of a nanoemulsion under the tongue of a subject from 30 seconds to 2 minutes, where the nanoemulsion comprises
- at least one monolayer surfactant bound particle, where
- the at least one monolayer surfactant bound particle comprises at least one amphiphilic fat, a polyethylene glycol surfactant, an associating oil, diindolylmethane, quercetin, and luteolin,
- the at least one monolayer surfactant bound particle has a ratio of the at least one amphiphilic fat to the polyethylene glycol surfactant from 1:1.8 to 1:3 by weight;
- and
- a continuous phase comprising glycerin, ethanol, and water;
- where
- the nanoemulsion is a stable dispersion that is transparent, and
- the at least one monolayer surfactant bound particle has an average particle diameter from 10 to 100 nanometers as carried by the continuous phase.
A method of making an intra-oral nanoemulsion for balancing histamine response in subjects when orally administered, the method comprising:
- forming a mixture comprising an amphiphilic fat chosen from phospholipid lecithin isolates and further comprising at least 30% by weight phosphatidylcholine, a polyethylene glycol surfactant, an associating oil, diindolylmethane, quercetin, luteolin, glycerin, ethanol, and water to form a nanoemulsion,
- where a ratio of the at least one amphiphilic fat to the polyethylene glycol surfactant is from 1:1.8 to 1:3 by weight;
- and
- stirring the nanoemulsion at room temperature and pressure to form a stable dispersion that is transparent and has an average particle diameter from 10 to 100 nanometers.
Dependencies are inferred from the claim text.